Patents Examined by Richard G Hutson
  • Patent number: 11965183
    Abstract: The invention relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: April 23, 2024
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Andrew John Heron, Rebecca Victoria Bowen, Mark Bruce, Lakmal Jayasinghe, Joseph Hargreaves Lloyd, Szabolcs Soeroes, Elizabeth Jayne Wallace, Christopher Peter Youd
  • Patent number: 11965188
    Abstract: The invention relates generally to recombinant human sialidases and recombinant sialidase fusion proteins, wherein the sialidase optionally contains one or more mutations compared to wild-type human sialidase, e.g., a substitution, deletion, or addition of at least one amino acid. The invention also provides antibody conjugates including a sialidase and an antibody or a portion thereof. The invention further relates to methods of using the sialidase fusion proteins or antibody conjugates for treating cancer.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: April 23, 2024
    Assignee: Palleon Pharmaceuticals Inc.
    Inventors: Li Peng, Lizhi Cao, Lihui Xu
  • Patent number: 11952598
    Abstract: Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes exhibit improved alpha-glucan product yields and/or lower leucrose yields, for example. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce alpha-glucan.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: April 9, 2024
    Assignee: NUTRITION & BIOSCIENCES USA 4, INC.
    Inventors: Yougen Li, Mark S. Payne, Jared B. Parker, Slavko Kralj, Veli Alkan, Richard R. Bott, Robert Dicosimo, Qiong Cheng, Ellen D. Semke, Susan Marie Hennessey
  • Patent number: 11946082
    Abstract: The present invention features fusion polypeptides comprising an RNA binding polypeptide operationally linked to an RNA modifying enzyme (e.g., adenosine deaminase, cytidine deaminase), and methods of use therefore.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: April 2, 2024
    Assignee: Brandeis University
    Inventors: Michael Rosbash, Aoife McMahon, Weijin Xu, Hua Jin
  • Patent number: 11939606
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: March 26, 2024
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 11932883
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: March 19, 2024
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 11926860
    Abstract: Provided are a method of screening an inhibitor of caspase activity by lipopolysaccharide and a method of screening a therapeutic agent for inflammatory diseases or sepsis using the same. Accordingly, it is possible to develop a caspase-4-specific inhibitor.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: March 12, 2024
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Hak Suk Chung, Jinsu An, Eun Gyeong Yang, So Yeon Kim
  • Patent number: 11920178
    Abstract: The present invention relates to the use of type III polyketide synthases of bacteria, such as actinomycete bacteria, as phloroglucinol synthases. The present invention also relates to the isolated nucleic acid molecules encoding these type III polyketide synthases, and also to the vectors and the host cells comprising such nucleic acid molecules. The present invention also relates to methods for producing phloroglucinol.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 5, 2024
    Assignee: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
    Inventors: Vincent Lafaquiere, Odile Ramaen, Dominique Louis
  • Patent number: 11913038
    Abstract: Provided are nucleic acids encoding engineered polymerases comprising at least one modification in a motif A and/or at least one modification in a motif B of the polymerase and engineered polymerases encoded by the nucleic acids. Also provided are engineered DNA polymerases comprising a variant of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, the variant being at least 80% identical to SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 and comprising an amino acid substitution at one or more positions selected from the group consisting of L408, Y409, P410, R484, A/L485, and I486. Methods, vectors, kits, and compositions comprising the nucleic acids and compositions, methods and kits comprising the engineered polymerases are also provided.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: February 27, 2024
    Assignee: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    Inventor: Pinar Iyidogan
  • Patent number: 11913044
    Abstract: Some aspects of this disclosure relate to strategies, systems, methods, compositions, and kits that are useful for production (e.g., evolution) of cytidine deaminase protein variants that are characterized by increased soluble expression and/or stability relative to the wild-type cytidine deaminase protein from which they are evolved. In some embodiments, evolved cytidine deaminase variants described by the disclosure are useful for incorporation into targeted nucleic acid editing proteins, for example in fusion proteins with a Cas9 domain or variant thereof.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: February 27, 2024
    Assignees: President and Fellows of Harvard College, The Broad Institute, Inc.
    Inventors: David R. Liu, Tina Wang
  • Patent number: 11912991
    Abstract: Embodiments of the disclosure concern methods and compositions related to generation and/or use of proofreading reverse transcriptases, including those that are thermophilic or hyperthermophilic. The disclosure encompasses specific recombinant polymerases and their use. In some embodiments, the polymerases are utilized for RNA sequencing in the absence of generation of a cDNA intermediate.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: February 27, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew Ellington, Jared Ellefson, Jimmy Gollihar
  • Patent number: 11891659
    Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing or nucleic acid amplification. Such properties include enhanced performance with large nucleotide analogs, increased stability, increased readlength, and improved detection of modified bases, and can also include resistance to photodamage, enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased accuracy, altered speed, increased cosolvent resistance, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: February 6, 2024
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Satwik Kamtekar, Erik Miller
  • Patent number: 11879154
    Abstract: The present disclosure belongs to the technical field of genetic modification of an enzyme preparation and particularly relates to a preparation method of a high-stability superoxide dismutase with a transmembrane capability. The method includes the following steps: extracting mRNA from Geobacillus stearothermophilus, synthesizing cDNA by a reverse transcription method, amplifying a large number of coding regions of the cDNA by designing a specific primer, ligating the coding regions to an E. coli expression vector, and transforming the coding regions into engineering bacteria BL21 (DE3). A point mutation technology is used to enhance stability of the superoxide dismutase and a flexible polypeptide linker GGGSGGGS (SEQ ID NO: 11) is designed, such that a soluble fusion expression of a transmembrane peptide YGRKKRRQRRR (SEQ ID NO: 10) and the superoxide dismutase is successfully realized.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: January 23, 2024
    Inventor: Yong Xia
  • Patent number: 11866740
    Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, recombinant polymerases and biologically active fragments thereof are provided that allow for nucleic acid amplification. In some aspects, the disclosure provides recombinant polymerases that yield lower systematic error rates and/or improved accuracy, when used in sequencing by synthesis reactions as compared to a control polymerase. In one aspect, the disclosure relates to recombinant polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In another aspect, the recombinant polymerases are useful for the amplification of nucleic acid templates during PCR, emPCR, isothermal amplification, recombinase polymerase amplification, rolling circle amplification, strand displacement amplification and proximity ligation amplification.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: January 9, 2024
    Assignee: Life Technologies Corporation
    Inventors: Daniel Mazur, Peter B. Vander Horn, Eileen Tozer, Sihong Chen, Guobin Luo, Joshua Shirley, Kevin Heinemann
  • Patent number: 11859247
    Abstract: The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently attached to the enzyme such that both the subunit and enzyme retain their activity. The constructs can be used to generate transmembrane protein pores having a nucleic acid handling enzyme attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect its component nucleotides by stochastic sensing.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: January 2, 2024
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Lakmal Jayasinghe, John Hagan Pryce Bayley, Stephen Cheley, Brian McKeown, James White, James Clarke
  • Patent number: 11834685
    Abstract: Covalently-linked DNA polymerases are provided.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: December 5, 2023
    Assignee: BIO-RAD LABORATORIES, INC.
    Inventor: Xiao-Song Gong
  • Patent number: 11827915
    Abstract: Enzymes and methods are described herein for manufacturing terpenes, including terpenes.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: November 28, 2023
    Assignee: Board of Trustees of Michigan State University
    Inventors: Björn Hamberger, Sean Johnson, Wajid Waheed Bhat
  • Patent number: 11814655
    Abstract: Provided are mutant polymerases having DNA polymerase activity and reverse transcriptase activity or strand displacement activity, along with target nucleic acid amplification methods employing such mutant polymerases.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: November 14, 2023
    Assignee: DNA POLYMERASE TECHNOLOGY, INC.
    Inventors: Wayne M. Barnes, Milko B. Kermekchiev, Zhian Zhang
  • Patent number: 11807887
    Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: November 7, 2023
    Assignee: Nuclera, Ltd.
    Inventors: Michael C. Chen, Radu A. Lazar, Jiahao Huang, Gordon R. McInroy
  • Patent number: 11807667
    Abstract: The present invention provides novel engineered polypeptides that support both reverse transcription and DNA amplification in manganese-independent reactions. The present invention also provides methods for amplifying template nucleic acids using such polypeptides. This invention addresses deficiencies in the current state of the art in nucleic acid amplification-based detection of template nucleic acids, especially RNA targets, including deficiencies in detection sensitivity, specificity, enzyme stability, inhibitor tolerance and time to result compared with manganese-dependent thermostable reverse transcriptases and two-enzyme solutions.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 7, 2023
    Assignee: QIAGEN BEVERLY, LLC.
    Inventors: Thomas William Schoenfeld, Ryan Charles Heller, Katarzyna Crissy, Suhman Chung